Sydney Lupkin
👤 SpeakerAppearances Over Time
Podcast Appearances
People with Medicare will be able to get them for a copay of $50 a month.
State Medicaid programs will have to opt in, but the lower cost of the drugs to the government, $245 per patient per month, is something that I'm hearing will likely push them toward this.
Novo Nordisk and Eli Lilly's blockbuster obesity and type 2 diabetes drugs are the centerpiece of agreements announced by the White House.
The drugs, Ozempic, Wegovy, Zepound, and Manjaro, will be available to the government at lower prices and to Medicare beneficiaries for a $50 copay.
The deals expand Medicare and Medicaid access for some but not all patients with obesity, and the arrangements would expand discounts available to patients buying the drugs through TrumpRx.gov, a website that is expected to launch before the end of the year.
The companies also promised that if experimental obesity pills they are developing win FDA approval, they will cost $149 per month for their starting doses.
Novo Nordisk and Eli Lilly's blockbuster obesity and type 2 diabetes drugs are the centerpiece of agreements announced by the White House.
The drugs, Ozempic, Wegovy, Zepound, and Manjaro, will be available to the government at lower prices and to Medicare beneficiaries for a $50 copay.
The deals expand Medicare and Medicaid access for some but not all patients with obesity, and the arrangements would expand discounts available to patients buying the drugs through TrumpRx.gov, a website that is expected to launch before the end of the year.
The companies also promised that if experimental obesity pills they are developing win FDA approval, they will cost $149 per month for their starting doses.
Yeah, it is super, super different.
And that's because weed on the federal level is illegal.
Pharmaceuticals, on the other hand, have to be approved by the Food and Drug Administration based on a very detailed process involving clinical trials and inspections to verify safety and efficacy.
With weed, that robust federal system is not there, which means that the states are basically having to figure this all out on their own and stand up their own
And they do have a group that they have sort of formed together called CANRA, which is basically a way for state regulators to communicate from state to state with one another to share data and what's working and what's not working.
But that has its limitations because the standards are still kind of a patchwork.
Yeah, so state officials had been doing this like across several different state agencies.